Physician profile
Scott Weber
NPI 1871517144
$15,894.40
in general payments reported to CMS, 2019-2025
41 companies · $237 in 2025
The $237 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,455 · 2020: $737 · 2021: $2,602 · 2022: $4,678 · 2023: $3,451 · 2024: $1,736 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,423.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,777.48 | 2019-2024 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $3,288.91 | 2019-2024 | Skyrizi, Rinvoq, Linzess |
| Pfizer INC. | $1,619.44 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,142.77 | 2019-2024 | Entyvio |
| Janssen Biotech, INC. | $1,093.99 | 2019-2023 | Stelara |
| Celgene Corporation | $888.71 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $878.43 | 2019-2024 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $509.31 | 2019-2023 | Dificid |
| Ferring Pharmaceuticals INC. | $476.36 | 2019-2023 | Rebyota |
| Braintree Laboratories, INC. | $219.46 | 2023-2024 | Suflave, Sutab |
| Daiichi Sankyo INC. | $202.26 | 2022-2024 | Injectafer |
| Ironwood Pharmaceuticals, INC | $200.28 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $183.38 | 2022-2024 | Dupixent |
| Genzyme Corporation | $172.62 | 2022-2024 | |
| Redhill Biopharma INC. | $141.60 | 2020-2023 | Talicia, Movantik, Aemcolo |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.